Literature DB >> 28126124

When More Isn't Better: Visits for Hypertension: Answers to the September 2016 Journal Club Questions.

Elizabeth M Goldberg1, Phillip D Levy2, Candace D McNaughton3.   

Abstract

Entities:  

Year:  2017        PMID： 28126124      PMCID： PMC8078484          DOI： 10.1016/j.annemergmed.2016.11.008

Source DB:  PubMed          Journal:  Ann Emerg Med        ISSN： 0196-0644            Impact factor:   5.721


× No keyword cloud information.
  17 in total

Review 1.  Hypertensive urgencies: treating the mercury?

Authors:  E John Gallagher
Journal:  Ann Emerg Med       Date:  2003-04       Impact factor: 5.721

2.  A Population-Based Analysis of Outcomes in Patients With a Primary Diagnosis of Hypertension in the Emergency Department.

Authors:  Sameer Masood; Peter C Austin; Clare L Atzema
Journal:  Ann Emerg Med       Date:  2016-07-06       Impact factor: 5.721

3.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

4.  Clinical policy: critical issues in the evaluation and management of adult patients with asymptomatic hypertension in the emergency department.

Authors:  Wyatt W Decker; Steven A Godwin; Erik P Hess; Carrie C Lenamond; Andy S Jagoda
Journal:  Ann Emerg Med       Date:  2006-03       Impact factor: 5.721

Review 5.  Clinical policy: critical issues in the evaluation and management of adult patients in the emergency department with asymptomatic elevated blood pressure.

Authors:  Stephen J Wolf; Bruce Lo; Richard D Shih; Michael D Smith; Francis M Fesmire
Journal:  Ann Emerg Med       Date:  2013-07       Impact factor: 5.721

6.  Safety and efficacy of antihypertensive prescription at emergency department discharge.

Authors:  Aaron Brody; Tahsin Rahman; Brian Reed; Scott Millis; Brian Ference; John M Flack; Phillip D Levy
Journal:  Acad Emerg Med       Date:  2015-04-22       Impact factor: 3.451

7.  Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Björn Dahlöf; Richard B Devereux; Sverre E Kjeldsen; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristiansson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

8.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  JAMA       Date:  2003-05-14       Impact factor: 56.272

9.  Characteristics and Outcomes of Patients Presenting With Hypertensive Urgency in the Office Setting.

Authors:  Krishna K Patel; Laura Young; Erik H Howell; Bo Hu; Gregory Rutecki; George Thomas; Michael B Rothberg
Journal:  JAMA Intern Med       Date:  2016-07-01       Impact factor: 21.873

10.  Optimal systolic blood pressure target, time to intensification, and time to follow-up in treatment of hypertension: population based retrospective cohort study.

Authors:  Wenxin Xu; Saveli I Goldberg; Maria Shubina; Alexander Turchin
Journal:  BMJ       Date:  2015-02-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.